Track the 지놈앤컴퍼니 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are listed on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 지놈앤컴퍼니 has published 49 insider filings. Market capitalisation: €122.7bn. The latest transaction was reported on 30 April 2026 (Purchase). Among the most active insiders: 배지수. Every trade is accessible without an account.
49
Insider Decl.
n/a
Thresholds
€45,606
8 ops.
Buy Volume
€88,901
4 ops.
Sell Volume
22Σ signal
Buys €45,606€88,901 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,548 of 28,753 companies
23.2
score / 100
Value
18
Quality
28
FCF yld-12%
Earn yld-4.3%
EV/EBITDA·
ROE-7.1%
Gross mgn55%
Net mgn-26%
Debt/EBITDA7.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Genome & Company is a healthcare and pharmaceutical company listed on the XKRX. It specializes in genomic technologies and personalized health solutions.